431 results on '"Fahrleitner-Pammer, Astrid"'
Search Results
2. Diagnose und Therapie der Osteoporose bei Patienten mit chronischer Niereninsuffizienz: Gemeinsame Leitlinie der Österreichischen Gesellschaft für Knochen- und Mineralstoffwechsel (ÖGKM), der Österreichischen Gesellschaft für Physikalische Medizin und Rehabilitation (ÖGPMR) und der Österreichischen Gesellschaft für Nephrologie (ÖGN)
3. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
4. Association of branched-chain amino acids with mortality-the Ludwigshafen Risk and Cardiovascular Health (LURIC) study
5. Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions
6. Usefulness of the trabecular bone score in maintenance dialysis patients: A single center observational study
7. Osteoporosis treatment in Austria—assessment of FRAX-based intervention thresholds for high and very high fracture risk
8. Thirty years of hip fracture incidence in Austria: is the worst over?
9. Morphometric parameters of muscle and bone in critically ill patients: Post hoc analysis of the VITdAL-ICU trial
10. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
11. Increased Early Postoperative Complication Rate after Osteoporotic Hip Fracture in Patients with Low 25 (OH) Vitamin D Levels.
12. Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction.
13. Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial
14. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
15. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
16. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment
17. Hospitalizations, emergency room visits and causes of death in 198 patients with permanent hypoparathyroidism: a retrospective Austrian study (2005–2022)
18. TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures
19. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk
20. Homoarginine in Patients With Primary Hyperparathyroidism
21. Serum sclerostin levels in renal cell carcinoma patients with bone metastases [Poster]
22. Diagnosis and treatment of osteoporosis in patients with chronic kidney disease
23. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
24. Autorenverzeichnis
25. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease
26. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
27. Morphometric parameters of muscle and bone in critically ill patients
28. Women Underrepresented on Editorial Boards of 60 Major Medical Journals
29. Awareness of chronic kidney disease in Austria: a frequently under-recognized clinical picture
30. Thirty years of hip fracture incidence in Austria: is the worst over?
31. Update on denosumab in postmenopausal osteoporosis—recent clinical data
32. Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS)
33. Osteoporosis, weight gain and atypical fat accumulations – a typical feature not only for Cushing's, but also Madelung's disease: A case report
34. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology – a review
35. Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: The GENOMOS study
36. Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose: Addendum 2010
37. Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences
38. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?
39. Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS)
40. Sclerostin in Institutionalized Elderly Women: Associations with Quantitative Bone Ultrasound, Bone Turnover, Fractures, and Mortality
41. Homoarginine, kidney function and cardiovascular mortality risk
42. Serum Sclerostin Levels Are Decreased in Adult Patients With Different Types of Osteogenesis Imperfecta
43. Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009
44. Bone - a casualty of ICU survival?
45. 700-P: Glucotab-Based Basal-Bolus Insulin Therapy for Inpatient Glycemic Control Using Insulin Degludec
46. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis
47. Hypovitaminosis D, impaired bone turnover and low bone mass are common in patients with peripheral arterial disease
48. Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status
49. Circulating aldosterone and mortality in female nursing home residents
50. 2011 — The Gender Gap Continues
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.